2009 Stem Cell Trendsetters in Neurology and Psychiatry. Brain Waves: The field of neurotechnology, the focus of this blog, encompasses advances in brain science (neurons), information technology (bits) and bioengineering (genes). Up for discussion and analysis: the political, economic, ethical, and social forces that will shape the future of what will be one of the most important and fascinating stories of the coming decades.

About this author

Zack Lynch is author of The Neuro Revolution: How Brain Science Is Changing Our World (St. Martin's Press, July 2009).
He is the founder and executive director of the Neurotechnology Industry Organization (NIO) and co-founder of NeuroInsights. He serves on the advisory boards of the McGovern Institute for Brain Research at MIT, the Center for Neuroeconomic Studies, Science Progress, and SocialText, a social software company. Please send newsworthy items or feedback - to Zack Lynch.
Follow me on Twitter at @neurorev

Receive by email

GUEST AUTHOR ARCHIVES

In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

« Mental Health Parity Legislation Passes within Financial Package | Main | Manuscript Sent to Japan »

October 15, 2008

2009 Stem Cell Trendsetters in Neurology and Psychiatry

Posted by Zack Lynch

Stem cell approaches in neurology and psychiatry is the focus of a new report released today by NeuroInsights, the neurotech market authority. The industry insider report on innovative research and development in stem cell technology for the brain and nervous system provides unique insights into the key players and competitive dynamics in this rapidly evolving field.

Stem cell companies focused on the central nervous system (CNS) have the potential to address some of the largest unmet healthcare markets including: Alzheimer's disease, amyotrophic lateral sclerosis, depression, hearing loss, Huntington's disease, lysosomal storage disorders, multiple sclerosis, Parkinson's disease, retinal disorders, spinal cord injury, stroke, traumatic brain injury, and other brain and nervous system disorders.

The report analyzes the scientific approaches and challenges to utilizing stem cells in the CNS, discusses trends and drivers including funding and regulatory issues, reveals promising treatment indications and pipelines, examines business models leveraging the promise of stem cells, and sheds light on investment opportunities and risks. It provides in-depth profiles of twenty seven companies that are shaping the field and spearheading the use of stem cells in the brain and nervous system.

The twenty seven trend setting companies reviewed in the report include: Aastrom Biosciences, Advanced Cell Technology, ArunA Biomedical, Athersys (Nasdaq: ATHX), Beike Biotechnology Company, BrainCells, Inc., BrainStorm Cell Therapeutics, California Stem Cell Inc., Cell Cure Neurosciences, CellMed AG, Geron Corporation (Nasdaq: GERN), International Stem Cell Corporation, NeuralStem, NeuroGeneration, NeuroNascent, NeuroNova AB, Neuronyx, NsGene A/S, Pfizer Regenerative Medicine, Q Therapeutics, ReNeuron Group (LSE: RENE.L), RhinoCyte, Stem Cell Sciences (LSE: STEM.L), Stem Cell Therapeutics (TSX: SSS.V), Stem Cell Technologies, StemCells, Inc. (Nasdaq: STEM), and Theradigm, Inc.

The 175 page report, "Stem Cell Approaches in Neurology and Psychiatry: 27 Trendsetters for 2009" is available immediately.

Comments (0) + TrackBacks (0) | Category: Neurotech Industry

POST A COMMENT

Thanks for signing in, . Now you can comment. (sign out)

(If you haven't left a comment here before, you may need to be approved by the site owner before your comment will appear. Until then, it won't appear on the entry. Thanks for waiting.)